PT  - JOURNAL ARTICLE
AU  - Carlijn E. Bruggeling
AU  - Maarten te Groen
AU  - Daniel R. Garza
AU  - Famke van Heeckeren tot Overlaer
AU  - Joyce P.M. Krekels
AU  - Basma-Chick Sulaiman
AU  - Davy Karel
AU  - Athreyu Rulof
AU  - Anne R. Schaaphok
AU  - Daniel L.A.H. Hornikx
AU  - Iris D. Nagtegaal
AU  - Bas E. Dutilh
AU  - Frank Hoentjen
AU  - Annemarie Boleij
TI  - BACTERIAL ONCOTRAITS BUT NOT BIOFILMS ARE ASSOCIATED WITH DYSPLASIA IN ULCERATIVE COLITIS
AID  - 10.1101/2022.09.09.22279675
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.09.22279675
4099  - http://medrxiv.org/content/early/2022/09/15/2022.09.09.22279675.short
4100  - http://medrxiv.org/content/early/2022/09/15/2022.09.09.22279675.full
AB  - Biofilms are polymeric matrices containing bacteria that can express oncotraits and are frequently present in ulcerative colitis (UC). Oncotraits can impact colon epithelial cells directly and may increase dysplasia risk. This study aimed to determine (1) the association of oncotraits and longitudinal biofilm presence with dysplasia risk in UC, and (2) the relation of bacterial composition with biofilms and dysplasia risk.In this prospective cohort study, feces and left- and right-sided colonic biopsies were collected from 80 UC patients and 35 controls. Oncotraits (FadA of Fusobacterium, BFT of Bacteroides fragilis, Colibactin (ClbB) and Intimin (Eae) of Escherichia coli) in fecal DNA were assessed with multiplex qPCR. Biopsies were analyzed for biofilms (n=873) with 16S rRNA fluorescent in situ hybridization and shotgun metagenomic sequencing (n=265), and ki67-immunohistochemistry for cell proliferation. Associations were determined with a regression (mixed) model.ClbB significantly associated with dysplasia in UC (aOR 7.16, (95%CI 1.75-29.28, p<0.01)), while FadA was inversely associated (aOR 0.23, (95%CI 0.06-0.83, p=0.03)). Patients with UC had a significantly lower Shannon diversity compared to controls (p=0.0009), as well as patients with a biofilm (p=0.015) independent of disease status. The order Fusobacteriales was significantly correlated with a decreased dysplasia risk only in right-sided colonic biopsies (p<0.01). Longitudinal biofilms were not significantly associated with dysplasia (aOR 1.45 (95% CI0.63-3.40, p=0.38)), however, biofilm-positive biopsies showed increased epithelial hypertrophy (p=0.025).Colibactin and FadA impact dysplasia risk in UC, in contrast to biofilms. These oncotraits are valuable targets for future risk classification and intervention studies.What is already known on this topic Bacterial biofilms sometimes contain bacteria with oncogenic traits (oncotraits) and have been associated with colon carcinogenesis in mice and humans. It is yet unknown whether biofilms and oncotraits are involved in early carcinogenesis and could be used as a risk factor for dysplasia in ulcerative colitis patients.What this study add Bacterial biofilms associated with lower bacterial diversity and epithelial cell hypertrophy, but did not predict dysplasia. Moreover, in agreement to piling evidence suggesting a role of colibactin in human colorectal cancer, we provide the missing clinical evidence that this oncotrait actually associates with risk for (early) carcinogenesis in human patients. Additionally, dysplasia in UC patients was predicted by absence of Fusobacterium adhesin.How this study might affect research, practice or policy This prospective cohort study indicates a putative role of bacterial oncotraits in early carcinogenesis, suggesting them as promising targets for future risk classification and intervention studies in ulcerative colitis patients.Lay summary Patients with ulcerative colitis have an increased risk for colorectal cancer. This study found that bacterial factors in fecal material can predict the development of cancer precursors in these patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Netherlands Organization for Scientific Research (NWO; Veni grant (016.166.089) to AB and Vidi grant (864.14.004) to BED), the Dutch cancer society (KWF-kankerberstrijding grant (KUN 2015-7739)), the European Research Council (ERC; Consolidator grant 865694: DiversiPHI to BED), the Netherlands Organization for Gastroenterology (NVGE; Gastrostart PROJECT 19-2021), and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany Excellence Strategy (EXC 2051, Project-ID 390713860) to BED.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee Commissie Mensgebonden onderzoek Arnhem-Nijmegen and the board of directors of the Radboudumc gave ethical approval for this work (NL55930.091.16)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw sequencing data with human reads will not be publicly available because of General Data Protection Regulation (GDPR). Processed sequencing data are available upon request. Anonymized patient and research data that support the findings of this study are openly available in supplementary data. IBDinflammatory bowel diseaseUCulcerative colitisPSCprimary sclerosing cholangitisCRCcolorectal cancerFDRFirst degree relativeHGDhigh-grade dysplasiaLGDlow-grade dysplasiaSSCAISimple Clinical Colitis Activity IndexORodds ratioaORadjusted odds ratioBFTBacteroides fragilis toxinqPCRquantitative PCRnnumberIQRinterquartile rangeIHCImmunohistochemistryFISHFluorescent in situhybridizationSDstandard deviationCIConfidence interval